Citigroup
TELO icon

Citigroup’s Telomir Pharmaceuticals TELO Stock Holding History

Citigroup’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$1 – 6472
2025
Q4 		$1 Hold
1
– – ﹤0.01% 5997
2025
Q3 		$1 Sell
1
-2,074
-100% -$3.13K ﹤0.01% 6048
2025
Q2 		$2.59K Sell
2,075
-11,810
-85% -$27.3K ﹤0.01% 5343
2025
Q1 		$44.8K Sell
13,885
-1,351
-9% -$5.91K ﹤0.01% 4901
2024
Q4 		$62.8K Buy
15,236
+11,750
+337% +$55.4K ﹤0.01% 5020
2024
Q3 		$22.4K Sell
3,486
-3,068
-47% -$15K ﹤0.01% 5169
2024
Q2 		$31.5K Sell
6,554
-11,194
-63% -$69.8K ﹤0.01% 4831
2024
Q1 		$92.8K Buy
+17,748
New +$134K ﹤0.01% 4326

Other funds holding TELO

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.2B AUM 19.68% 1-Year Est. Return

Citigroup's TELO Position: Q1 2026 in Review

Citigroup sold out of Telomir Pharmaceuticals (TELO) in Q1 2026, closing a stake of 1 share — an estimated $1 sold.

Citigroup first reported a position in TELO in Q1 2024 and held it in 8 quarters. The position peaked at $92.8K in Q1 2024. 27 funds tracked by Wall St. Rank hold TELO as of Q1 2026.

  • Citigroup reported no remaining Telomir Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 1 Telomir Pharmaceuticals share in Q1 2026, an estimated $1.
  • Citigroup first reported a position in Telomir Pharmaceuticals in Q1 2024 and held it in 8 quarters.
  • Citigroup's Telomir Pharmaceuticals position peaked at $92.8K in Q1 2024.
  • 27 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.